Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice.
Key claim: In aged atherosclerotic mice, rapamycin reduced plaque macrophage content and remodeled systemic and vascular immunity toward regulatory T-cell phenotypes while suppressing effector T/B responses and senescent leukocyte signatures.
Abstract
Aging is a major risk factor for atherosclerosis and is accompanied by profound changes in the immune system, including effector T cell expansion, senescent cell accumulation, and increased pro-inflammatory signaling. Rapamycin, a promising rejuvenation therapeutic that inhibits mTORC1 and modulates immune aging, was investigated for its potential to attenuate pro-atherogenic immune responses in aged atherosclerotic mice. 80- to 90-week-old male Ldlrmice with established atherosclerotic lesions were treated intraperitoneally with rapamycin or control triweekly for 8 weeks. Systemic and plaque immunity was assessed by flow cytometry or single-cell RNA-sequencing. Plaque morphology was evaluated by histology. Rapamycin treatment reduced plaque macrophage content (0.73 ± 0.07 × 10 μm) compared to control (ctrl: 0.95 ± 0.09 × 10 μm, p < 0.05) and decreased total T cell numbers in vascular and lymphoid tissues. This was accompanied by a shift from effector to central memory phenotypes, particularly within the CD8compartment, and a relative enrichment of regulatory CD4T cells (Tregs). Single-cell transcriptomics of aortic Tregs revealed increased expression of suppressive genes (Foxp3, Tgfb1) upon rapamycin. Rapamycin also reduced T follicular helper cells, IL-21 expression, germinal center B cells, plasma cells, and total and oxidation-specific epitope-specific immunoglobulin levels. Additionally, age-associated B cells were diminished in spleen and lymph nodes, reflecting a broader anti-inflammatory effect on B cell immunity. Finally, aortic leukocytes displayed profoundly reduced senescent enrichment scores. Rapamycin remodels the immune landscape in aged atherosclerotic mice, promoting regulatory lymphocyte subsets and suppressing antigen-driven and inflammatory immune responses. These findings highlight the potential of immune-targeted rejuvenation to mitigate age-related atherogenic inflammation.
Why this matters
Rapamycin’s aging story has mostly rested on lifespan extension in model organisms and cardiac/atrial remodeling data; this adds a direct, cell-resolved look at how systemic mTOR inhibition reshapes the immune ecosystem inside established atherosclerotic plaque in aged animals. It links three mechanism threads the vault tracks separately — mTOR, senescent leukocytes, and immunosenescent lymphoid skew — in a single preclinical experiment, strengthening the mechanistic case while leaving the human-translation gap untouched.